Antimicrobial Susceptibility Breakpoints
- 1 January 2005
- journal article
- Published by Springer Nature in Treatments in Respiratory Medicine
- Vol. 4 (1) , 5???11-11
- https://doi.org/10.2165/00151829-200504001-00004
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Impact of pharmacodynamics on breakpoint selection for susceptibility testingInfectious Disease Clinics of North America, 2003
- European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteriaJournal of Antimicrobial Chemotherapy, 2003
- Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef (A) or erm (B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug ConcentrationsAntimicrobial Agents and Chemotherapy, 2002
- Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC BreakpointAntimicrobial Agents and Chemotherapy, 2001
- Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime timeCurrent Opinion in Microbiology, 2000
- Determination of antimicrobial susceptibility test breakpointsClinical Microbiology & Infection, 2000
- Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteersAntimicrobial Agents and Chemotherapy, 1997
- Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testingAntimicrobial Agents and Chemotherapy, 1980
- A RESISTANT PNEUMOCOCCUSThe Lancet, 1967
- Antibiotic Susceptibility Testing by a Standardized Single Disk MethodAmerican Journal of Clinical Pathology, 1966